
## Mitsuteru Natsuizaka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3266550/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical features of hepatocellular carcinoma with extrahepatic metastases. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1781-1787.	1.4	432
2	Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. Nature Communications, 2017, 8, 1758.	5.8	155
3	Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. Nature Protocols, 2012, 7, 235-246.	5.5	138
4	Epidermal Growth Factor Receptor and Mutant p53 Expand an Esophageal Cellular Subpopulation Capable of Epithelial-to-Mesenchymal Transition through ZEB Transcription Factors. Cancer Research, 2010, 70, 4174-4184.	0.4	128
5	NOTCH1 and NOTCH3 Coordinate Esophageal Squamous Differentiation Through a CSL-Dependent Transcriptional Network. Gastroenterology, 2010, 139, 2113-2123.	0.6	107
6	Hypoxia activates the cyclooxygenase-2–prostaglandin E synthase axis. Carcinogenesis, 2010, 31, 427-434.	1.3	104
7	Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. Journal of Gastroenterology, 2016, 51, 733-740.	2.3	103
8	A NOTCH3-Mediated Squamous Cell Differentiation Program Limits Expansion of EMT-Competent Cells That Express the ZEB Transcription Factors. Cancer Research, 2011, 71, 6836-6847.	0.4	99
9	Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Experimental Cell Research, 2007, 313, 3337-3348.	1.2	72
10	Insulin-like growth factor-binding protein-3 promotes transforming growth factor-β1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. Carcinogenesis, 2010, 31, 1344-1353.	1.3	72
11	L arnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis. Hepatology Communications, 2018, 2, 910-922.	2.0	67
12	Fibroblast growth factor-2–mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. Carcinogenesis, 2017, 38, 1073-1083.	1.3	64
13	8â€Hydroxyâ€2â€2â€deoxyâ€guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1431-1436.	1.4	58
14	IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. American Journal of Cancer Research, 2014, 4, 29-41.	1.4	50
15	Human Amnion-Derived Mesenchymal Stem Cell Transplantation Ameliorates Dextran Sulfate Sodium-Induced Severe Colitis in Rats. Cell Transplantation, 2015, 24, 2601-2614.	1.2	46
16	EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition. Cancer Biology and Therapy, 2015, 16, 933-940.	1.5	46
17	Hypoxia induces IGFBP3 in esophageal squamous cancer cells through HIFâ€1αâ€mediated mRNA transcription and continuous protein synthesis. FASEB Journal, 2012, 26, 2620-2630.	0.2	44
18	Inhibition of Notch signaling enhances transdifferentiation of the esophageal squamous epithelium towards a Barrett's-like metaplasia via KLF4. Cell Cycle, 2014, 13, 3857-3866.	1.3	42

MITSUTERU NATSUIZAKA

#	Article	IF	CITATIONS
19	Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a realâ€world setting. JGH Open, 2020, 4, 54-60.	0.7	36
20	Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. Hepatology Research, 2020, 50, 966-977.	1.8	35
21	CTNNB1 mutational analysis of solid-pseudopapillary neoplasms of the pancreas using endoscopic ultrasound-guided fine-needle aspiration and next-generation deep sequencing. Journal of Gastroenterology, 2015, 50, 203-210.	2.3	33
22	Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor-κB/mitogen-activated protein kinase. Carcinogenesis, 2014, 35, 272-281.	1.3	32
23	Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. Journal of Gastroenterology, 2017, 52, 1122-1129.	2.3	32
24	Entecavir treatment of hepatitis B virusâ€infected patients with severe renal impairment and those on hemodialysis. Hepatology Research, 2019, 49, 1294-1304.	1.8	32
25	Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma. Abdominal Imaging, 2015, 40, 1492-1499.	2.0	31
26	Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virusâ€infected patients with renal impairment. Hepatology Research, 2017, 47, 1127-1136.	1.8	31
27	Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS ONE, 2018, 13, e0209615.	1.1	29
28	Tenofovir–disoproxil–fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. Journal of Gastroenterology, 2021, 56, 168-180.	2.3	29
29	Metformin Regulates the Expression of CD133 Through the AMPK-CEBPÎ <sup>2</sup> Pathway in Hepatocellular Carcinoma Cell Lines. Neoplasia, 2019, 21, 545-556.	2.3	28
30	Analysis of the optimal psoas muscle mass index cutâ€off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. Hepatology Research, 2020, 50, 715-725.	1.8	28
31	Prevalence and characteristics of naturally occurring sofosbuvir resistanceâ€associated variants in patients with hepatitis C virus genotype 1b infection. Hepatology Research, 2016, 46, 1294-1303.	1.8	27
32	Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells. Journal of Experimental and Clinical Cancer Research, 2017, 36, 101.	3.5	27
33	A pivotal role of Krüppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma. Cancer Biology and Therapy, 2015, 16, 1453-1461.	1.5	22
34	Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapyâ€associated hepatitis in Japan. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1782-1788.	1.4	22
35	Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. Journal of Hepatology, 2017, 67, 1106-1108.	1.8	21
36	Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. Journal of Gastroenterology, 2019, 54, 641-649.	2.3	21

MITSUTERU NATSUIZAKA

#	Article	IF	CITATIONS
37	Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1–3 signaling, but not FGFR4 signaling. Carcinogenesis, 2021, 42, 58-69.	1.3	21
38	Anti-adipogenic and antiviral effects of <scp>l</scp> -carnitine on hepatitis C virus infection. Journal of Medical Virology, 2017, 89, 857-866.	2.5	20
39	High serum angiopoietinâ€2 level predicts nonâ€regression of liver stiffness measurementâ€based liver fibrosis stage after directâ€acting antiviral therapy for hepatitis C. Hepatology Research, 2020, 50, 671-681.	1.8	20
40	Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. Hepatology Research, 2021, 51, 979-989.	1.8	20
41	Notch receptor inhibition reveals the importance of cyclin D1 and Wnt signaling in invasive esophageal squamous cell carcinoma. American Journal of Cancer Research, 2012, 2, 459-75.	1.4	20
42	Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. Journal of Gastroenterology, 2019, 54, 78-86.	2.3	19
43	Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. Hepatology Research, 2019, 49, 1207-1217.	1.8	19
44	Diffuse Large B-cell Lymphoma with Massive Portal Vein Tumor Thrombosis in a Patient with Alcoholic Cirrhosis: A Case Report and Literature Review. Internal Medicine, 2009, 48, 805-808.	0.3	17
45	ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma. Journal of Clinical Pathology, 2016, 69, 593-599.	1.0	17
46	Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PLoS ONE, 2022, 17, e0261760.	1.1	17
47	Serum granulysin levels as a predictor of serious telaprevirâ€induced dermatological reactions. Hepatology Research, 2015, 45, 837-845.	1.8	15
48	Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. Hepatology Research, 2018, 48, 529-538.	1.8	15
49	Baseline angiopoietinâ€⊋ and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. JGH Open, 2020, 4, 880-888.	0.7	13
50	Timeâ€dependent changes in the seroprevalence of COVIDâ€19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVIDâ€19. Hepatology Research, 2020, 50, 1196-1200.	1.8	11
51	Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. Cancers, 2021, 13, 3633.	1.7	10
52	Sensitive Assay for Quantification of Hepatitis B Virus Mutants by Use of a Minor Groove Binder Probe and Peptide Nucleic Acids. Journal of Clinical Microbiology, 2010, 48, 4487-4494.	1.8	9
53	Effects of resistanceâ€associated variants in genotype 2Âhepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs. Hepatology Research, 2019, 49, 1275-1285.	1.8	8
54	Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. JCSM Rapid Communications, 2020, 3, 103-114.	0.6	8

MITSUTERU NATSUIZAKA

#	Article	IF	CITATIONS
55	Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. Scientific Reports, 2021, 11, 9207.	1.6	8
56	Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia. Nutrients, 2021, 13, 2415.	1.7	8
57	Hepatosplenic Gamma-delta T-cell Lymphoma Associated with Epstein-Barr Virus. Internal Medicine, 2014, 53, 2079-2082.	0.3	6
58	Changes in the estimated renal function after hepatitis C virus eradication with directâ€acting antiviral agents: Impact of changes in skeletal muscle mass. Journal of Viral Hepatitis, 2021, 28, 755-763.	1.0	6
59	Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals. Scientific Reports, 2021, 11, 16616.	1.6	6
60	Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 2022, 14, 232.	1.7	6
61	The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. Internal Medicine, 2019, 58, 943-947.	0.3	5
62	MMP7 and activation of IGF-1R: A new insight into anti-EGFR therapeutic resistance in metastatic colorectal cancer. Cancer Biology and Therapy, 2011, 11, 184-187.	1.5	4
63	The nuclear protein Artemis promotes AMPK activation by stabilizing the LKB1–AMPK complex. Biochemical and Biophysical Research Communications, 2012, 427, 790-795.	1.0	4
64	Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. Internal Medicine, 2019, 58, 797-802.	0.3	4
65	Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy. World Journal of Gastrointestinal Oncology, 2021, 13, 2076-2087.	0.8	4
66	Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. PLoS ONE, 2021, 16, e0247728.	1.1	3
67	FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma. Cancer Biology and Therapy, 2021, 22, 372-380.	1.5	3
68	Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. Hepatology Research, 2018, 48, E146-E154.	1.8	1
69	Can Stressed Blood Cells Tell Cancer Risk in Inflammatory Bowel Diseases?. Gastroenterology, 2009, 137, 2174-2175.	0.6	0